103426-20-6

Basic information

• Product Name: 3-chloro-5-methylbenzaldehyde
• Synonyms: 3-chloro-5-methylbenzaldehyde;3-Methyl-5-chlorobenzaldehyde
• CAS NO: 103426-20-6
• Molecular Formula: C₈H₇ClO
• Molecular Weight: 155
• Mol File: 103426-20-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-chloro-5-methylbenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-5-methylbenzaldehyde(103426-20-6)
• EPA Substance Registry System: 3-chloro-5-methylbenzaldehyde(103426-20-6)

Safety Data

• Hazardous Substances Data: 103426-20-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-5-methylbenzaldehyde is used as a reactant in the synthesis of 1,2-diarylimidazoles, which are cyclooxygenase selective and orally active anti-inflammatory agents. These agents play a crucial role in the development of new drugs for the treatment of inflammation and related conditions, such as arthritis and other pain-related disorders.
In the synthesis of 1,2-diarylimidazoles, 3-chloro-5-methylbenzaldehyde serves as a key intermediate, providing the necessary structural features and reactivity required for the formation of the final product. The compound's chlorine atom and methyl group contribute to the overall molecular structure and properties of the resulting anti-inflammatory agents, enhancing their selectivity and efficacy.
The use of 3-chloro-5-methylbenzaldehyde in the pharmaceutical industry highlights its importance as a synthetic building block and its potential in the development of novel therapeutic agents. Its unique structural features and reactivity make it a valuable component in the design and synthesis of new drugs, particularly in the area of anti-inflammatory medications.

Upstream product

• 79-37-8 oxalyl dichloride 
• 62358-81-0 1-(bromomethyl)-3-chloro-5-methylbenzene 
• 189161-09-9 3-chloro-5-methylbenzonitrile 
• 556-97-8 1-chloro-3,5-dimethylbenzene 

Downstream Products

• 189161-09-9 3-chloro-5-methylbenzonitrile 
• 177661-46-0 2-(3-chloro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole 
• 177661-14-2 4-[2-(3-chloro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide 
• 1027488-95-4 2-(3-Chloro-5-methyl-phenyl)-1-(4-methanesulfonyl-phenyl)-4-trifluoromethyl-4,5-dihydro-1H-imidazol-4-ol 
• 56961-33-2 3-Chloro-5-Methylbenzoic Acid 
• 115-20-8 1,1,1-trichloroethanol 

Relevant articles and documents

Cyanation of arenes via iridium-catalyzed borylation

We report a method to conduct one-pot meta cyanation of arenes by iridium-catalyzed C-H borylation and copper-mediated cyanation of the resulting arylboronate esters. This process relies on a method to conduct the cyanation of arylboronic esters, and conditions for this new transformation are reported. Conditions for the copper-mediated cyanation of arylboronic acids are also reported. By the resulting sequence of borylation and cyanation, 1,3-disubstituted and 1,2,3-trisubstituted arenes and heteroarenes containing halide, ketone, ester, amide, and protected alcohol functionalities are converted to the corresponding meta-substituted aryl nitriles. The utility of this methodology is demonstrated through the conversion of a protected 2,6-disubstituted phenol to 4-cyano-2,6-dimethylphenol, which is an intermediate in the synthesis of the pharmaceutical etravirine. The utility of the method is further demonstrated by the conversion of 3-chloro-5-methylbenzonitrile, produced through the one-pot C-H borylation and cyanation sequence, to the corresponding 3,5-disubstituted aldehydes, ketones, amides, carboxylic acids, tetrazoles, and benzylamines.

Inhibitors of Serine Proteases

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.

INHIBITORS OF SERINE PROTEASES

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.

5-amino or substituted amino 1,2,3-triazoles

Novel 5-amino or substituted amino 1,2,3-triazoles are disclosed as having anticoccidial activity. The compounds are useful for controlling coccidiosis when administered in minor quantities to animals, in particular to poultry, usually in admixture with animal sustenance.